HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

prof.Dr. Hossam M. Hassan , College of Pharmacy, University of Kut,Iraq

Dr. Hossam Mokhtar Hassan 🇪🇬 is an esteemed Associate Professor of Pharmacognosy at Nahda University and Beni-Suef University, Egypt 🧪. With a Ph.D. in Pharmaceutical Sciences and postdoctoral training at UCSD’s Scripps Institute 🌊, his expertise lies in natural product chemistry, marine pharmacognosy, and phytotherapy 🌿. He currently serves as Vice-Dean for Postgraduate Affairs and General Manager of the Central Research Lab at NUB 🧫. A dedicated educator and researcher, he has received multiple accolades 🏆 and remains active in scientific societies, pushing the boundaries of drug discovery from natural and marine sources 🔬.

Professional Profile:

Scopus

🎓 Education & Experience 

🎓 Education:

  • 🧪 Ph.D. in Pharmaceutical Sciences, University of Louisiana & Beni-Suef University, 2010

  • 🌿 M.Sc. in Pharmacognosy, Cairo University, 2006

  • 💊 B.Sc. in Pharmaceutical Sciences (Honors), Cairo University, 2000

  • 🌊 Postdoc at Scripps Institute of Oceanography, UCSD, 2013-2014

💼 Experience:

  • 🏛️ Vice-Dean for Postgraduate Affairs, Faculty of Pharmacy, NUB (2019–Present)

  • 👨‍🏫 Associate Professor, Nahda & Beni-Suef Universities (2016–Present)

  • 🧪 General Manager, Central Research Lab, NUB (2017–Present)

📈 Professional Development 

Dr. Hassan has continually honed his skills through international fellowships and academic training 🧳. He has mastered advanced techniques such as NMR, HPLC, LC/MS, GC/MS, and molecular docking for natural product analysis 🔬🧫. His scientific capabilities span pharmacophore modeling, phytochemistry, and marine bioprospecting 🌊🌱. He has also developed leadership skills as a strategic planning team leader at NUB 🗂️, with training in effective teaching, decision-making, communication, and problem-solving 🎯🗣️. His active memberships in the American Society of Pharmacognosy and the Egyptian Syndicate of Pharmacists reflect his commitment to global scientific communities 🌍📚.

🔍 Research Focus Category 

Dr. Hassan’s research is centered on natural product drug discovery, especially from marine and plant-derived sources 🌊🌿. He isolates bioactive compounds from symbiotic bacteria, fungi, and medicinal plants to explore their pharmacological potential 💊. His work involves biotransformation, chemical derivatization, and 3D-QSAR studies for structure–activity relationships 🧪🧬. His expertise in phytochemistry and marine pharmacognosy contributes to identifying novel therapeutic agents against microbial infections, cancer, and fertility disorders 🔬👨‍⚕️. Integrating cutting-edge analytical and modeling techniques, he aims to harness nature’s biodiversity for modern medicine 🌍🧫.

🏆 Awards & Honors 

  • 🏅 Best Master’s Thesis, Faculty of Pharmacy, Cairo University, 2006

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2007

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2012

  • 🎓 Best Ph.D. Thesis in Pharmacognosy, All Egyptian Pharmacy Faculties, 2012

Publication Top Notes:

1. Pachycladins A–E: Eunicellin-Based Diterpenoids

Hassan HM, Khanfar MA, Elnagar AY, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Pachycladins A–E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the Red Sea soft coral Cladiella pachyclados. J Nat Prod. 2010; 73(5):848–853.
https://doi.org/10.1021/np900858m

🔬 Summary:
This study reports the isolation of five new Eunicellin-based diterpenoids, named Pachycladins A–E, from the Red Sea soft coral Cladiella pachyclados. These compounds were shown to inhibit the migration and invasion of prostate cancer cells, indicating promising anticancer potential through marine natural product chemistry.

2. 3D-QSAR of Semisynthetic Eunicellin Diterpenoids

Hassan HM, Elnagar AY, Khanfar MA, Sallam A, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Design and 3D-quantitative structure-activity relationship of semisynthetic eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors. Eur J Med Chem. 2011; 46(4):1122–1130.
https://doi.org/10.1016/j.ejmech.2011.01.055

🧪 Summary:
The paper explores the design and synthesis of semisynthetic derivatives of eunicellin-based diterpenoids and develops a 3D-QSAR model to evaluate their anticancer activity. These analogs demonstrated enhanced inhibition of prostate cancer cell migration and invasion, highlighting their potential for further drug development.

3. Semisynthetic Sarcophine Derivatives as Anticancer Agents

Hassan HM, Sallam AA, Mohammed R, Hifnawy MS, Youssef DT, El Sayed KA. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors. Bioorg Med Chem. 2011; 19(16):4928–4934.
https://doi.org/10.1016/j.bmc.2011.06.073

🧬 Summary:
This study details the synthesis of analogues of sarcophine, a marine cembranoid, and evaluates their ability to inhibit migration in prostate and breast cancer cell lines. Several derivatives showed strong bioactivity, offering new leads in anticancer drug discovery.

4. Decorosides A and B: Cytotoxic Flavonoid Glycosides

Mostafa ER, Hossam MH, El-Shaimaa AA, Marcel J, Rainer E. Decorosides A and B, cytotoxic flavonoid glycosides from the leaves of Rhododendron decorum. Nat Prod Commun. 2014; 9(4):473–476.
https://doi.org/10.1177/1934578X1400900408

🌿 Summary:
The article reports the isolation of two new flavonoid glycosides—Decorosides A and B—from Rhododendron decorum. Both compounds exhibited cytotoxic effects, contributing to the growing interest in plant-derived anticancer agents.

5. Salinamide F: A Marine-Derived Depsipeptide Antibiotic

Hossam MH, David D, Kyoung HJ, Richard HE, William F. Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp. J Antibiot. 2015; 68(3):206–210.
https://doi.org/10.1038/ja.2014.127

🧫 Summary:
This paper describes the discovery of Salinamide F, a novel depsipeptide isolated from Streptomyces sp.. The compound functions as a potent inhibitor of bacterial RNA polymerase, demonstrating promise as a new class of antibiotic against resistant bacteria.

6. Bioactivity of Pulicaria undulata Metabolites

Taha AH, Sayed AE-T, Hossam MH, Mona HH. Cytotoxic and antioxidant activities of secondary metabolites from Pulicaria undulata. Int J Pharm Pharm Sci. 2016; 8(9):150–155.
https://innovareacademics.in/journals/index.php/ijpps/article/view/13208

🌼 Summary:
The study investigates secondary metabolites from Pulicaria undulata, demonstrating both cytotoxic and antioxidant activities. It highlights the plant’s potential as a natural source of therapeutic agents targeting oxidative stress and cancer.

Conclusion:

Prof. Dr. Hossam M. Hassan exemplifies the qualities of a Best Researcher Award recipient through:

  • Innovative scientific contributions in natural products and pharmaceutical chemistry,

  • Strategic academic leadership and international collaboration,

  • Sustained impact on public health-oriented drug discovery.

His work not only advances science but also addresses critical global health challenges such as cancer, antibiotic resistance, and oxidative stress disorders.

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Posted on by ScienceFather

Ms. Moloud Farrokhi | Nanodelivery Awards | Best Researcher Award

Ms. Moloud Farrokhi , Albany Medical college, United States

Mouloud Farrokhi is an experienced immunologist and microbiologist specializing in HIV/AIDS research, nanoparticle delivery systems, and viral infections. He is currently pursuing a PhD in Biology with a focus on Immunology and Microbiology at Albany Medical College, USA. Mouloud has a strong academic and professional background, having worked as a research assistant and medical laboratory scientist in Iran and Sweden. His research aims to improve understanding and treatment of viral infections, with significant contributions to HIV drug resistance and oncolytic virus therapy. Mouloud’s work also extends to the development of innovative nanoparticle-based drug delivery systems, offering promising solutions for invasive infections like Aspergillosis. His expertise spans from molecular biology to clinical research, with an emphasis on laboratory techniques like PCR, qRT-PCR, NGS, and CRISPR/Cas9.

Professional Profile:

Google Scholar

Mouloud Farrokhi: A Strong Contender for the Research Best Researcher Award

Mouloud Farrokhi is an exceptional candidate for the Research Best Researcher Award due to his extensive background in immunology, microbiology, and viral infections, as well as his significant contributions to molecular diagnostics and therapeutic innovations. His educational qualifications, research experience, and recognition in the field of medical sciences make him a highly suitable candidate for this prestigious award.

🎓Education:

Mouloud Farrokhi is currently pursuing a PhD in Biology, specializing in Immunology and Microbiology at Albany Medical College, USA (2023–Present). He holds two Master’s degrees: an MSc in Bioscience from the University of Skövde, Sweden (2021–2022), with a thesis on the role of RABL6 in AP3-dependent trafficking, and an MSc in Cellular and Molecular Biology from the Islamic Azad University, Iran (2010–2014), where he researched HIV-1 drug resistance. His undergraduate studies were in Marine Biology at the Islamic Azad University, Tehran, Iran (2003–2008). Mouloud’s extensive education in biological sciences provides a solid foundation for his current research endeavors, focusing on viral infections, molecular diagnostics, and therapeutic innovations.

🏢Experience:

Mouloud Farrokhi has gained extensive experience as a research assistant and medical laboratory scientist. He worked as a Research Assistant at Tehran University of Medical Sciences (2022–2023), where he focused on statistical analysis and NGS (Next Generation Sequencing). He has also served as a Medical Laboratory Assistant at Tehran University of Medical Sciences (2018–2021), where he conducted HIV viral load analysis and COVID-19 testing via qPCR. His previous roles include being a Medical Laboratory Scientist at Dena Lab (2017–2018), where he performed NITP tests and a Research Assistant at Pasteur Institute of Iran (2016–2017), where he researched drug resistance in HIV and HCV. He has also contributed to laboratory work at Keyvan Virology Laboratory, Tehran (2015–2016). Mouloud’s diverse hands-on experience makes him proficient in molecular biology techniques, data analysis, and lab management.

🏅Awards and Honors:

Mouloud Farrokhi’s academic and research achievements are reflected in his high academic standing and contributions to scientific research. His thesis at the University of Skövde received top marks, with a GPA of 3.75, and he has consistently demonstrated excellence throughout his academic career. His research contributions have been recognized in various publications and presentations. Notably, he presented at the International Student Congress in Medical Sciences (ISCOM) in 2017 and at the Upstate New York Immunology Conference (NYIC) in 2024. Mouloud’s work in HIV drug resistance and nanoparticle drug delivery systems has been published in high-impact journals. His dedication to advancing medical science has led to multiple research opportunities, including participation in workshops on gene transfer and vaccine design.

🔬Research Focus:

Mouloud Farrokhi’s research focuses on immunology, microbiology, and the molecular mechanisms underlying viral infections and drug resistance. He investigates the molecular pathways of HIV and other viral infections, focusing on drug resistance mechanisms in HIV-1 and HCV. His research also explores innovative strategies for oncolytic virus therapy and nanoparticle-based drug delivery, with the goal of improving treatment outcomes for invasive infections like Aspergillosis. Additionally, he is involved in genetic analysis and genomic editing technologies such as CRISPR/Cas9. Mouloud’s work integrates molecular diagnostics and therapeutic advancements, contributing significantly to both basic science and clinical applications in virology and immunology.

Publication Top Notes:

  • “Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013”
    • Citations: 31
  • “HIV drug resistance among naïve HIV-infected patients in Iran”
    • Citations: 14
  • “Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran”
    • Citations: 11
  • “The first characterization of HIV-1 subtypes and drug resistance mutations among antiretrovirally treated patients in Kermanshah, Iran”
    • Citations: 9
  • “HIV drug resistance and phylogeny profile in naive and antiretroviral-experienced patients in Tehran, Iran”
    • Citations: 8

 

 

 

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Posted on by ScienceFather

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skiba’s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

🎓Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in Châtenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

🏢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated Attaché in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

🏅Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

🔬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARS‐CoV‐2 Main Proteases
  • Development of a Novel Cyclodextrin–Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Posted on by ScienceFather

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano,University of Pisa,Italy

Angela Fabiano is a senior researcher at the University of Pisa, Department of Pharmacy, specializing in drug delivery systems. She earned her Ph.D. in Science of Drugs and Bioactive Substances in 2016, with a focus on innovative pharmaceutical systems based on chitosan and its derivatives. Her research involves the synthesis, purification, and characterization of chitosan derivatives to enhance solubility and pharmaceutical applications, including nanosystems and hydrogels for drug delivery via ocular and oral routes. In 2020, she achieved the scientific qualification for associate professor and has authored over 30 publications, with around 800 citations.

Professional Profile:

Orcid

Scopus

Suitability for Best Researcher Award:

Angela Fabiano’s innovative research in drug delivery systems, significant academic contributions, and recognized scientific qualifications make her an outstanding candidate for the Best Researcher Award. Her work directly impacts the development of novel pharmaceutical systems, positioning her as a leader in her field.

🎓Education:

Angela Fabiano earned her Ph.D. in Science of Drugs and Bioactive Substances from the University of Pisa in 2016. Her doctoral thesis, titled “Innovative Pharmaceutical Systems Based on Chitosan and Its Derivatives,” focused on developing novel pharmaceutical systems using chitosan and its derivatives. Her research explored the synthesis, purification, and characterization of these derivatives to improve solubility and expand their pharmaceutical applications, particularly in the creation of advanced drug delivery systems. This work laid the foundation for her continued contributions to drug delivery research.

🏢Work Experience:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, specifically the synthesis, purification, and characterization of chitosan derivatives. She is dedicated to advancing the development of nanosystems and hydrogels for drug delivery through various routes, including ocular and oral. Her work aims to enhance the effectiveness and versatility of pharmaceutical applications, contributing significantly to the field of drug delivery.

🏅Awards & Achievements:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, including the synthesis, purification, and characterization of chitosan derivatives. She is also involved in the development of advanced nanosystems and hydrogels for drug delivery through ocular and oral routes. In 2020, she achieved scientific qualification for the role of Associate Professor at the University of Pisa. She has authored over 30 publications in journals with medium to high impact factors, and her work has been cited approximately 800 times, underscoring her significant contributions to the field.

Publication Top Notes:

  • Title: Cross-Linked Thiolated Hydroxypropyl-β-Cyclodextrin for Pulmonary Drug Delivery
  • Title: Olive Leaf Extracts from Three Italian Olive Cultivars Exposed to Drought Stress Differentially Protect Cells against Oxidative Stress
  • Title: Betaine- and L-Carnitine-Based Ionic Liquids as Solubilising and Stabilising Agents for the Formulation of Antimicrobial Eye Drops Containing Diacerein
  • Title: Bergamot Essential Oil: A Method for Introducing It in Solid Dosage Forms
  • Title: Thiolated Hydroxypropyl-β-Cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery

 

 

 

 

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Posted on by ScienceFather

Assoc. Prof. Dr. Kyeong Soo Kim | Pharmaceutics Awards | Excellence in Research

Assoc. Prof. Dr. Kyeong Soo Kim  , Gyongsang National University/Dept. of Pharmaceutical Engineering , South Korea

Kyeong Soo Kim is an accomplished researcher and academic based in the Republic of Korea. He currently serves as an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University. Dr. Kim earned his Ph.D. in Pharmacy from Hanyang University, where he specialized in the development of novel controlled release formulations for fenofibric acid. His research interests span nanotechnology applications for poorly water-soluble drugs, improved pharmaceutical technologies for controlled release dosage forms, inhaled drug delivery systems, and dermal drug delivery systems. Prior to his current position, he held roles as a Postdoctoral Research Associate at the University of Mississippi and as a Principal Scientist at Hanmi Pharm. Co., Ltd., where he gained extensive experience in formulation and process development. Dr. Kim’s expertise includes designing oral and parenteral dosage forms, conducting preformulation studies, and utilizing advanced techniques such as solid dispersion, spray drying, and lipid-based formulations to enhance drug delivery efficacy. He is actively involved in research and has contributed significantly to the field through his publications and professional engagements.

Professional Profile:

Scopus

🎓Education:

Kyeong Soo Kim is a distinguished academic and researcher in the field of pharmacy, currently holding the position of Associate Professor at Gyeongsang National University in the Republic of Korea. He completed his Ph.D. in Pharmacy at Hanyang University from March 2011 to August 2015, under the guidance of Professor Han-Gon Choi, Ph.D. His doctoral research focused on the development of innovative controlled release formulations for fenofibric acid. Prior to his doctoral studies, he earned a Master of Science in Pharmacy at Chungbuk National University from March 2002 to August 2004, where his research investigated the depigmenting effects and mechanisms of piperlonguminine derived from Piper longum. Kyeong Soo Kim began his academic journey with a Bachelor of Science in Pharmacy, also from Chungbuk National University, completed from March 1998 to February 2002. His educational background underscores his expertise in pharmaceutical sciences, particularly in drug delivery systems and formulation development.

 🏢Work Experience:

Kyeong Soo Kim is currently an Associate Professor in the Department of Pharmaceutical Engineering at Gyeongsang National University in the Republic of Korea, a position he has held since September 2017. Prior to joining Gyeongsang National University, Dr. Kim served as a Postdoctoral Research Associate at the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, USA, from September 2016 to August 2017. Before his time in the United States, he worked as a Postdoctoral Research Fellow at the Laboratory of Industrial & Physical Pharmacy at Hanyang University, Republic of Korea, from September 2015 to August 2016. Dr. Kim’s extensive professional experience also includes a significant tenure as a Principal Scientist and Team Manager at the Pharmaceutical R&D Center of Hanmi Pharm. Co., Ltd., Republic of Korea, where he contributed from August 2004 to November 2014. His career path highlights his expertise in pharmaceutical engineering, drug delivery systems, and research leadership in both academic and industrial settings.

Publication Top Notes:

  • “Improved bioavailability and high photostability of methotrexate by spray-dried surface-attached solid dispersion with an aqueous medium” by Giri, B.R., Kim, J.S., Park, J.H., … Choi, H.G., Kim, D.W.
    • Journal: Pharmaceutics, 2021, 13(1), pp. 1–14, 111
    • Citations: 36
  • “Nitration of protein phosphatase 2A increases via Epac1/PLCε/CaMKII/HDAC5/iNOS cascade in human endometrial stromal cell decidualization” by Lee, S.Y., Lee, Y.Y., Choi, J.-S., … Park, S.-Y., Han, J.-S.
    • Journal: FASEB Journal, 2020, 34(11), pp. 14407–14423
    • Citations: 2
  • “Development of Novel d-Cycloserine Tablet with Improvement of Drug Stability and Dissolution-Equivalence to the d-Cycloserine-Loaded Commercial Hard Capsule” by Kim, J.S., Choi, Y.J., Woo, M.R., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(6), pp. 603–608
    • Citations: 3
  • “Enhanced Chemical Stability of D-Cycloserine via Tablet Form Containing Magnesium Oxide as an Alkali Stabilizer” by Kim, J.S., Lee, S.M., Kim, D.S., … Jin, S.G., Choi, H.-G.
    • Journal: Bulletin of the Korean Chemical Society, 2020, 41(1), pp. 10–14
    • Citations: 1
  • “Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate” by Kim, D.S., Cho, J.H., Park, J.H., … Choi, H.-G., Kim, D.W.
    • Journal: International Journal of Nanomedicine, 2019, 14, pp. 4949–4960
    • Citations: 61